JNJ
The headline is doing a little misdirection
Sure, the title talks about Robeco trimming its J&J stake. But that’s mostly old-school portfolio housekeeping — the real fresh meat here is J&J’s Q1 update. The company beat expectations with $2.70 in EPS and $24.06 billion in revenue, then turned around and nudged its FY2026 EPS guide higher to $11.45–$11.65.
Why investors care
That combo matters because it says J&J can still juggle the usual corporate circus: patent cliffs, tariff noise, and the never-ending battle of making giant healthcare look boring in a good way. A raised guide after a beat usually tells you management isn’t just polishing the brass; it thinks the engine has more room to run.
And yes, the dividend crowd got fed too
J&J also bumped its quarterly dividend to $1.34, marking its 64th straight annual increase. That’s not just a nice little trophy on the shelf — it’s a reminder that this is still one of the market’s classic cash-machine names, the kind retirees and long-term holders like to keep in the family photo album.
The bigger picture
The stock may still be dealing with tariff-related worries and the usual “what about tomorrow?” questions, but this update gives bulls a fresh talking point: J&J is still generating enough momentum to beat, raise, and pay up all at once. Big picture: when a megacap healthcare name keeps checking those boxes, Wall Street tends to stay interested.